HEALTH OF WOMAN. 2016.9(115):103–111; doi 10.15574/HW.2016.115.103 
 

Breast cancer in reproductive age, inducers of risk and the role of vitamin D

Veropotvelyan P. N., Tsekhmistrenko I. S., Veropotvelyan N. P., Yaruchik S. P., Stepanovich I. V.

OKU «Interregional centre of medical genetics and prenatal diagnosis», Krivoy Rog

Perinatal center, Kiev

KU "Kryvyi Rih Oncology dispensary" DOS"

The article presents the inductors risk of developing breast cancer (RGI).

Сonsidering the risks of breast cancer in women in different age periods, appropriate use of targeted cancer protector and symptomatic therapy. Gene polymorphism of the vitamin D, the different expression of enzymes involved in the synthesis of biologically active forms of vitamin D and catabolism of vitamin ultimately determine the local concentration of the vitamin D. the Latter regulates the proliferation of breast cells which is the basis of benign lesions and cancer of the breast. Timely correction of vitamin D deficiency is one of the most effective methods for primary prevention of breast cancer.

Key words: breast cancer, inductors risk of breast cancer, vitamin D, vitamin D receptor gene polymorphism of vitamin D, mastodynia, dishormonal disease of the breast.

REFERENCES

1. Clinical Effectiveness Unit. Contraception for women aged 40 years. London (England): Faculty of Sexual and Reproductive Healthcare (FSRH):26. 2010, Jul.

2. Thorbjarnardottir T, Olafsdottir EJ, Valdimarsdottir UA, Olafsson O, Tryggvadottir L. 2014. Oral contraceptives, hormone replacement therapy and breast cancer risk: A cohort study of 16 928 women 48 years and older. Acta Oncol. 53:752-8. https://doi.org/10.3109/0284186X.2013.878471 ; PMid:24460068

3. Wilson AR, Marotti L, Bianchi S, Biganzoli L, Claassen S, Decker T et al. 2013. EUSOMA (European Society of Breast Cancer Specialists). The requirements of a specialist Breast Centre. Eur. J. Cancer. 49(17):3579-87.

4. Fiuza-Luces C, Garatachea N, Berger NA, Lucia A. 2013. Exercise is the real polypill. Physiology (Bethesda) 28(5):330-58. https://doi.org/10.1152/physiol.00019.2013

5. Yamamoto N, Suyama H, Ushijima N. 2008. Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF). Int. J. Cancer. 122(2):461-7.

6. Dragoslava Zivadinovic, Watson Cheryl S. 2005. Membrane estrogen receptor- alpha levels predict estrogeninduced ERK Ѕ activation in MCF-7 cells. Breast Cancer Res. 7:130-114. https://doi.org/10.1186/bcr959; PMid:15642162 PMCid:PMC1064105

7. Smolanka II. 2016. Vzglyad onkologa na reproduktivnoe zdorove zhenschinyi. Z turbotoyu pro zhInku 4(70):11-12.

8. Radzinsky VE, Ordiyants IM, Maslennikov MN, Pavlova EA, Kardanova VV. 2013. The possibility of a combination therapy of uterine fibroids and benign mammary dysplasia. Obstetrics and Gynecology 4:44-47.

9. Chung JG. 1999. Effects of butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) on the acetylation of 2-aminofluorene and DNA-2-aminofluorene adducts in the rat. Toxicol Sci. 51(2):202-10. https://doi.org/10.1093/toxsci/51.2.202; PMid:10543022

10. Maltsevа LI, Haryfullova Y. 2015. Vitamin D and breast cancer in women gland. Obstetrics and Gynecology 8:33-38.

11. Novikovа VA. 2015. Factors line breast cancer glands in the reproductive age. Obstetrics and Gynecology 10:27-34.

12. Socolov D, Anghelache I, Ilea C, Socolov R, Carauleanu A. 2015. Benign breast disease and the risk of breast cancer in the next 15 years. Rev. Med. Chir. Soc. Med. Nat. Iasi. 119(1):135-40.

13. Dyrstad SW, Haryfullova Y. 2015. Breast cancer risk associated with benign breast disease: systematic review and meta-analysis. Breast Cancer Res. Treat. 149(3):569-75.

14. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A et al. 2015. Breast Cancer Version 2.2015. J. Natl. Compr. Canc. Netw. 13(4):448-75.

15. Bellcross C. 2009. Approaches to applying breast cancer risk prediction models in clinical practice. Commun. Oncol. 6(8):373-82.

16. Emets NA. 2016. Rol progesterona v terapii disgormonalnyih zabolevaniy MZh. Ot teorii k prakticheskomu primeneniyu. Z turbotoyu pro zhinku 5(71):16-17.

17. Boonyaratanakornkit V, Pateetin P. 2015. The role of ovarian sex steroids in metabolic homeostasis, obesity, and postmenopausal breast cancer: molecular mechanisms and therapeutic implications. Biomed. Res. Int. 2015. Article ID 140196.

18. Brisken C, O’Malley B. 2010. Hormone action in the mammary gland. Cold Spring Harb. Perspect. Biol. 2(12):a003178.

19. Xie M, Zhou L, Chen X, Gainey LO, Xiao J, Nanes MS et al. 2015. Progesterone and Src family inhibitor PP1 synergistically inhibit cell migration and invasion of human basal phenotype breast cancer cells. Biomed. Res. Int. 2015:Article ID 426429.

20. Melander O, Orho-Melander M, Manjer J, Svensson Th, Almgren P, Nilsson PM et al. 2015. Stable peptide of the endogenous opioid enkephalin precursor and breast cancer risk. J. Clin. Oncol. 33(24):2632-8.

21. Joung KH, Jeong J-W, Ku BJ. 2015. The association between type 2 diabetes mellitus and women cancer: the epidemiological evidences and putative mechanisms. Biomed. Res. Int. 2015:Article ID 920618.

22. Institute of Medicine, Food and Nutrition Board. Dietary reference intakes for calcium and vitamin D. Washington, DC: National Academy Press. 2010

23. Bischoff-Ferrari HA, Burckhardt P, Quack-Loetscher K, Gerber B, I’Allemand D, Laimbacher J, Bachmann M, Rizzoli R. 2012. Vitamin D deficiency: evidence, safety, and recommendations for the Swiss population. Report written by a group of experts on behalf of the Federal Commission for Nutrition (FCN). Available at: http: //www. iccidd. org/ p142000804. html. 3.

24. Dawson-Hughes B, Mithal A, Bonjour JP, Boonen S, Burckhardt P, Fuleihan GE et al. 2010. IOF position statement: vitamin D recommendations for older adults. Osteoporos. Int. 21(7):1151-4. https://doi.org/10.1007/s00198-010-1285-3

25. Elamin MB, Abu Elnour NO, Elamin KB, Fatourechi MM, Alkatib AA, Almandoz JP et al. 2011. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 96(7):1931-42. https://doi.org/10.1210/jc.2011-0398; PMid:21677037

26. Mitri J, Pittas AG. 2014. Vitamin D and diabetes. Endocrinol. Metab. Clin. North Am. 43(1):205-32. https://doi.org/10.1016/j.ecl.2013.09.010; PMid:24582099 PMCid:PMC3942667

27. Ooi LL, Zhou H, Kalak R, Zheng Y, Conigrave AD, Seibel MJ, Dunstan CR. 2010. Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis. Cancer Res. 70(5):1835-44. https://doi.org/10.1158/0008-5472.CAN-09-3194; PMid:20160035

28. Garland C, Garland F, Gorham E. 1999. Epidemiology of cancer risk and vitamin D. In: Holick M., ed. Vitamin D: molecular biology, physiology, and applications. Totowa, New Jersey, Humana Press:375-409.

29. John EM, Schwartz GG, Dreon DM, Koo J. 1999. Vitamin D and breast cancer risk: the NHANES I Epidemiologic follow-up study, 1971-1975 to 1992. National Health and Nutrition Examination Survey. Cancer Epidemiol. Biomarkers Prev. 8(5):399-406. PMid:10350434

30. Gorham ED, Garland CF, Garland FC. 1989. Acid haze air pollution and breast and colon cancer in 20 Canadian cities. Can. J. Public Health 80(2):96-100. PMid:2720547

31. Garland CF, Gorham ED, Mohr SB, Grant WB, Giovannucci EL, Lipkin M et al. 2007. Vitamin D and prevention of breast cancer: pooled analysis. J. Steroid Biochem. Mol. Biol. 103(3-5):708-11. https://doi.org/10.1016/j.jsbmb.2006.12.007; PMid:17368188

32. Rejnmark L, Tietze A, Vestergaard P, Buhl L, Lehbrink M, Heickendorff L, Mosekilde L. 2009. Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study. Cancer Epidemiol. Biomarkers Prev. 18(10):2655-60. https://doi.org/10.1158/1055-9965.EPI-09-0531; PMid:19789365

33. Toner CD, Davis CD, John A, Milner JA. 2010. The vitamin D and cancer conundrum: aiming at a moving target. J. Am. Diet. Assoc. 110(10):1492-500. https://doi.org/10.1016/j.jada.2010.07.007; PMid:20869488

34. Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N. 2009. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J. Clin. Oncol. 27(23):3757-63. https://doi.org/10.1200/JCO.2008.20.0725; PMid:19451439

35. Colston KW. 2008. Vitamin D and breast cancer risk. Best Pract. Res. Clin. Endocrinol. Metab. 22(4):587-99.

36. Zinser GM, Suckow M, Welsh J. 2005. Vitamin D receptor (VDR) ablation alters carcinogen-induced tumorigenesis in mammary gland, epidermis and lymphoid tissues. J. Steroid Biochem. Mol. Biol. 97(1-2):153-64. https://doi.org/10.1016/j.jsbmb.2005.06.024; PMid:16111884

37. McCullough ML, Bostick RM, Mayo TL. 2009. Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu. Rev. Nutr. 29:111-32. https://doi.org/10.1146/annurev-nutr-080508-141248; PMid:19400699

38. Raimondi S, Johansson H, Maisonneuve P, Gandini S. 2009. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis 30(7):1170-80. https://doi.org/10.1093/carcin/bgp103; PMid:19403841

39. Tang C, Chen N, Wu M, Yuan H, Du Y. 2009. Fok1 polymorphism of vitamin D receptor gene contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res. Treat. 117(2):391-9. https://doi.org/10.1007/s10549-008-0262-4; PMid:19145484

40. Colin EM, Weel AE, Uitterlinden AG, Buurman CJ, Birkenhдger JC, Pols HA, van Leeuwen JP. 2000. Consequences of vitamin D receptor gene polymorphisms for growth inhibition of cultured human peripheral blood mononuclear cells by 1, 25-dihydroxyvitamin D3. Clin. Endocrinol. (Oxford). 52(2):211-6. https://doi.org/10.1046/j.1365-2265.2000.00909.x

41. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. 2004. Genetics and biology of vitamin D receptor polymorphisms. Gene. 338(2):143-56. https://doi.org/10.1016/j.gene.2004.05.014; PMid:15315818

42. Mehta RG, Peng X, Alimirah F, Murillo G, Mehta R. 2013. Vitamin D and breast cancer: emerging concepts. Cancer Lett. 334(1):95-100. https://doi.org/10.1016/j.canlet.2012.10.034; PMid:23142286

43. Dalessandri KM, Miike R, Wiencke JK, Farren G, Pugh TW, Manjeshwar S et al. 2012. Vitamin D receptor polymorphisms and breast cancer risk in a high-incidence population: a pilot study. J. Am. Coll. Surg. 215(5):652-7. https://doi.org/10.1016/j.jamcollsurg.2012.06.413; PMid:22867716

44. Lundin AC, Soderkvist P, Eriksson B, Bergman-Jungestrom M, Wingren S. 1999. South-East Sweden Breast Cancer Group. Association of breast cancer progression with a vitamin D receptor gene polymorphism. Cancer Res. 59(10):2332-4. PMid:10344739

45. Lowe LC, Guy M, Mansi JL, Peckitt C, Bliss J, Wilson RG, Colston KW. 2005. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotypes and breast cancer risk in a UK Caucasian population. Eur. J. Cancer. 41(8):1164-9. https://doi.org/10.1016/j.ejca.2005.01.017; PMid:15911240

46. Lopes N, Sousa B, Martins D, Gomes M, Vieira D, Veronese LA et al. 2010. Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer. 10:483. Available at: http://www.biomedcentral.com/1471-2407/10/483. https://doi.org/10.1186/1471-2407-10-483; PMid:20831823 PMCid:PMC2945944

47. Hereditary Breast and/or Ovarian Cancer Syndrome. NCCN Guidelines Version 4.2013.Available at: http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed October 30, 2013.

48. Lanfranchi AE, Fagan P. Breast cancer and induced abortion: a comprehensive review of breast development and pathophysiology, the epidemiologic literature, and proposal for creation of databanks to elucidate all breast cancer risk factors. Issues Law Med. 29(1):3-133. 2014 Spring. PMid:25189012

49. Radzinsky VE, Ordiyants IM, Hasanova LK, Toktar LR, Zubkin VI. 2010. Breast and gynecological disease. Moscow: 304.

50. Del Prete A, Allavena P, Santoro G, Fumarulo R, Corsi MM, Mantovani A. 2011. Molecular pathways in cancer-related inflammation. Biochem. Med. (Zagreb) 21(3):264-75. https://doi.org/10.11613/BM.2011.036

51. Rouzvia SK. 2004. Gynecology. Almost Directory doctor. Per. with English. Ailamazyan EK, ed. M, MEDpress –inform:519.

52. Fei Ch, DeRoo LA, Sandler DP, Weinberg CR. 2012. Fertility drugs and young-onset breast cancer: results from the Two Sister Study. J. Natl. Cancer Inst. 104(13):1021-7. https://doi.org/10.1093/jnci/djs255; PMid:22773825 PMCid:PMC3634553

53. Scoccia B, Moghissi K, Westhoff C, Niwa S, Ruggieri D, Trabert B et al. 2014. O-064 Long-term relationship of ovulation-stimulating drugs to breast and gynecologic cancers. In: Abstracts of the 30th Annual Meeting of the European Society of Human Reproduction and Embryology. 29 June – 2 July 2014 Munich, Germany. Hum. Reprod. 29(1): i27.

54. Tanday S. 2014. Fertility drugs not linked to cancer risk. Lancet. Oncol. 15(9):367. doi: http: //dx. doi. org/10. 1016/S1470-2045(14)70300-6

55. Podzolkova NM, Kuznetsov IV. 2006. AL Eye Obesity and Function reproduktyvnaya women. Uchebnoe posobye. M:28.

56. Khawaja A, Thompson ChL, Rao S, Li L. 2013. Sleep duration and breast cancer phenotype. J. Cancer Epidemiol. 2013: Article ID 467927. https://doi.org/10.1155/2013/467927; PMid:24319459 PMCid:PMC3834985

57. Haider MH, Satpathy A, Abou-Samra W. 2014. Iatrogenic arteriovenous fistula of the breast as a complication of core needle biopsy. Ann. R. Coll. Surg. Engl. 96(8):e20-2. https://doi.org/10.1308/003588414X13946184903162; PMid:25350171 PMCid:PMC4474130

58. Manshadi Deghan S, Ishiguro L, Sohn K-J, Medline A, Renlund R, Croxford R, Kim YI. 2014. Folic acid supplementation promotes mammary tumor progression in a rat model. PLoS One. 9(1):84635. https://doi.org/10.1371/journal.pone.0084635; PMid:24465421 PMCid:PMC3897399

59. Beaber EF, Buist DSM, Barlow WE, Malone KE, Reed SD, Li CI. 2014. Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age. Cancer Res. 74(15):4078–89. https://doi.org/10.1158/0008-5472.CAN-13-3400; PMid:25085875 PMCid:PMC4154499

60. Gierisch JM, Coeytaux RR, Peragallo Urrutia R, Havrilesky LJ, Moorman PG, Lowery WJ et al. 2013. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol. Biomarkers Prev. 22(11):1931–43. https://doi.org/10.1158/1055-9965.EPI-13-0298; PMid:24014598

61. Hou N, Hong S, Wang W, Olopade OI, Dignam JJ, Huo D. 2013. Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. J. Natl. Cancer Inst. 105(18):1365–72. https://doi.org/10.1093/jnci/djt207; PMid:24003037 PMCid:PMC3776262

62. http: // onkolog-24.ru/rak-molochnoy-zhelezy-u-zhenshchin.html

63. Okulov AB, Brovin DN, Volodko EA. 2005. Hypospadias and gynecomastia markers of disorders sex differentiation. Attending physician. 7:28–32.

64. Schwartz G.Y. vitamin D Deficiency and its pharmacological correction. Regular issues of «BC» No. 7 dated 06.04.2009 page 477.

65. Kochetkova EA, Degemerzanova NK. 2013, July-August. Cancer risk breast and ovarian cancer caused by mutations of genes BRCA1, BRCA2, CHEK2. Kazakhstan Medical Journal 4(34).